Invited discussant, Ursula Matulonis, MD, Chief of the Division of Gynecologic Oncology at Dana-Farber Cancer Institute, Boston, applauded the improved outcomes favoring lenvatinib/pembrolizumab in t...
In the first report from the pivotal phase III KEYNOTE-775/Study 309 trial, the combination of lenvatinib, a multikinase inhibitor of VEGFR1, VEGFR2, and VEGFR3 kinases, and pembrolizumab significantl...
Anthony B. Costales, MD, of the Baylor College of Medicine, discusses results from the MIID-SOC trial, which explored the question of whether laparoscopic surgery for removal of ovarian, fallopian tub...
Two studies presented at the Society of Gynecologic Oncology (SGO) 2021 Annual Meeting on Women’s Cancer highlighted the importance of addressing racial inequities in gynecologic cancers, including im...
Andreas Obermair, MD, of the University of Queensland and Queensland Centre for Gynaecological Cancer Research, discusses data on a hormonal IUD used to treat women with the precursor lesion endometri...
Amir A. Jazaeri, MD, of The University of Texas MD Anderson Cancer Center, discusses data on the safety and efficacy of adoptive cell transfer using autologous tumor-infiltrating lymphocytes (LN-145) ...
Eric Pujade-Lauraine, MD, PhD, of Hôpital Hôtel-Dieu, discusses results from the PAOLA-1ENGOT-ov25 trial on the use of homologous recombination–repair mutation gene panels and whether they can predict...
Brittany A. Davidson, MD, of Duke University, discusses the development and validation of the GO-POP model (Gynecologic Oncology Predictor of Postoperative opioid use), an individualized patient-cente...
Dana M. Roque, MD, of the University of Maryland Medical Center, discusses phase II results showing that weekly ixabepilone plus biweekly bevacizumab may improve overall response rate as well as progr...
Laura Chambers, DO, of the Cleveland Clinic, discusses data showing that combining paclitaxel and cisplatin vs cisplatin alone with hyperthermic intraperitoneal chemotherapy at interval debulking surg...
Supriya Chopra, MD, of Tata Memorial Centre, discusses a final analysis of the phase III PARCER trial, which showed that image-guided intensity-modulated radiotherapy is superior to conventional radio...
Lauren Thomaier, MD, of the University of Minnesota, discusses the genetic variants found to be associated with an increase in chemotherapy-induced neuropathy symptoms in a cohort of gynecologic canc...
Emily Hinchcliff, MD, MPH, of The University of Texas MD Anderson Cancer Center, discusses phase II results of durvalumab (anti–PD-L1) and tremelimumab (anti–CTLA-4) administered in combination vs seq...
Sandro Pignata, MD, PhD, of the Istituto Nazionale dei Tumori, discusses results from the ORZORA trial, which showed the efficacy of olaparib in patients with platinum-sensitive relapsed ovarian cance...
Alice P. Barr, MD, of the Carolinas Medical Center and Levine Cancer Institute, discusses results from a retrospective study, which showed that progression-free and overall survival appeared to be no ...
Treatment with image-guided intensity-modulated radiotherapy (IG-IMRT) led to reduced late toxicities vs standard three-dimensional (3D) conformal radiotherapy in patients with cervical cancer, accord...
The addition of niraparib maintenance to first-line platinum-based chemotherapy with bevacizumab demonstrated clinical benefit in patients with advanced ovarian cancer, according to data from the OVAR...
Charles N. Landen, MD, of the University of Virginia, discusses results from the first clinical trial in ovarian cancer to demonstrate that neither a BRCA1/2 mutation nor a homologous recombination de...
Hyun C. Chung, MD, of Yonsei Cancer Center and Yonsei University College of Medicine, discusses phase II findings from the KEYNOTE-158 study, which support the use of pembrolizumab for patients with r...
An intrauterine device, or IUD, that releases the hormone levonorgestrel appears to be an effective treatment for endometrial precancer and early-stage endometrial cancer, according to new study resul...
Shannon N. Westin, MD, of The University of Texas MD Anderson Cancer Center, discusses phase II results from the ENPAC trial, which showed the combination of enzalutamide, paclitaxel, and carboplatin ...
In the 5-year follow-up of the pivotal SOLO-1 trial in women with advanced ovarian cancer and a BRCA1/2 mutation, maintenance treatment with olaparib led to a doubling in progression-free survival. Wi...
Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute, discusses phase III results from the ENGOT-OV16/NOVA study on the long-term safety and efficacy of niraparib as maintenance therapy in patient...
The PARP (poly [ADP-ribose] polymerase) inhibitor niraparib is safe for long-term use and effective as maintenance treatment in patients with platinum-sensitive recurrent ovarian cancer, according to ...
In patients with BRCA-mutated, advanced, relapsed ovarian cancer, treatment with the PARP (poly [ADP-ribose] polymerase) inhibitor rucaparib led to a significant improvement in progression-free surviv...
Frailty may be a better predictor of poor surgical outcomes in patients with ovarian cancer than age, according to two studies reported at the Society of Gynecologic Oncology (SGO) 2021 Virtual Annual...
Morcos N. Nakhla, MS, a second-year student at the David Geffen School of Medicine at UCLA, discusses data showing that a higher surgical volume is associated with better outcomes for frail patients u...
Brian M. Slomovitz, MD, of Florida International University, describes how emphasizing diversity and shifting away from clinical trials at universities helped The GOG Foundation, Inc., increase patien...
Edward L. Trimble, MD, MPH, of the National Cancer Institute, discusses the World Health Organization’s global strategy to speed the elimination of cervical cancer through vaccination, screening, trea...
William H. Bradley, MD, of the Medical College of Wisconsin, discusses results from the SOLO-1 trial on maintenance olaparib after first-line platinum-based chemotherapy for patients with newly diagno...
Although some studies show that patients with cancer have a greater risk of health complications from COVID-19, a new study has found that recent chemotherapy or immunotherapy for gynecologic cancer d...
Treatment with olaparib is safe and effective for patients with platinum-sensitive relapsed ovarian cancer, regardless of the number of prior lines of chemotherapy received and BRCA mutation status, a...
In a survey of 250 female gynecologic oncologists, more than half reported experiencing instances of bullying, gender discrimination, or microaggressions. They also reported that having a female depar...
In the first report from the pivotal phase III KEYNOTE-775/Study 309 trial, the combination of lenvatinib and pembrolizumab significantly improved multiple outcomes compared to standard single-agent c...
Rebecca S. Kristeleit, MD, PhD, of the University College London and UCL Cancer Institute, discusses efficacy and safety results from the phase III ARIEL4 study, which showed that rucaparib improved p...
Vicky Makker, MD, of Memorial Sloan Kettering Cancer Center, discusses phase III findings showing that lenvatinib plus pembrolizumab may improve overall and progression-free survival, as well as overa...